专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20110152345A1 EBI3, DLX5, NPTX1 AND CDKN3 FOR TARGET GENES OF LUNG CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： EBI3，DLX5，NPTX1和CDKN3用于肺癌治疗和诊断的靶基因
公开(公告)号：US20110152345A1
公开(公告)日：2011-06-23
申请号：US12674759
申请日：2008-08-21
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： A61K31/713 , C07H21/00 , C12N15/63 , C12Q1/68 , C12Q1/02 , G01N33/68 , G01N33/53 , C12Q1/42 , A61P35/00
CPC分类号： A61K31/70 , A61K38/00 , A61K2039/505 , C07K14/4702 , C07K16/22 , C07K16/244 , C07K16/3023 , C07K2317/34 , C07K2317/73 , C07K2317/77 , C12N15/113 , C12N2310/111 , C12N2310/14 , G01N33/57423 , G01N2800/54
摘要： The present invention relates to methods for treating or preventing lung cancer by administering a double-stranded molecule against one or more of EBI3, DLX5, NPTX1, CDKN3 or EF-I delta genes or compositions, vectors or cells containing such a double-stranded molecule. The present invention also features methods for diagnosing lung cancer, especially NSCLC or SCLC, using one or more over-expressed genes selected from among EBI3, DLX5, NPTX1, CDKN3 and/or EF-I delta. Also disclosed are methods of identifying compounds for treating and preventing lung cancer, using as an index their effect on the over-expression of one or more of EBI3, DLX5, CDKN3 and/or EF-I delta in the lung cancer, the cell proliferation function of one or more of EBI3, DLX5, NPTX1, CDKN3 and/or EF-I delta or the interaction between CDKN3 and VRS, EF-I beta, EF-I gamma and/or EF-I delta.
摘要翻译：本发明涉及通过对EBI3，DLX5，NPTX1，CDKN3或EF-1δ基因中的一种或多种施用双链分子或组合物，载体或含有这种双链分子的细胞来治疗或预防肺癌的方法。本发明还涉及使用一种或多种选自EBI3，DLX5，NPTX1，CDKN3和/或EF-1δ的过度表达的基因来诊断肺癌，特别是NSCLC或SCLC的方法。还公开了用于鉴定用于治疗和预防肺癌的化合物的方法，以其作为指标对肺癌中EBI3，DLX5，CDKN3和/或EF-1δ中的一种或多种的过表达的作用，细胞增殖 EBI3，DLX5，NPTX1，CDKN3和/或EF-1δ中的一种或多种的功能或CDKN3和VRS，EF-1β，EF-1γ和/或EF-1δ之间的相互作用。

22. 发明申请

US20100173317A1 METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCER 失效
标题翻译：用于诊断非小细胞肺癌的方法
公开(公告)号：US20100173317A1
公开(公告)日：2010-07-08
申请号：US12700669
申请日：2010-02-04
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： C12Q1/68
CPC分类号： A61K31/731 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： Disclosed are methods for detecting non-small cell lung cancer (NSCLC) using differentially expressed genes KIF11, GHSR1b, NTSR1, and FOXM1. Also disclosed are methods of identifying compounds for treating and preventing NSCLC, based on the interaction between KOC1 and KIF11, or NMU and GHSR1b or NTSR1.
摘要翻译：公开了使用差异表达基因KIF11，GHSR1b，NTSR1和FOXM1检测非小细胞肺癌（NSCLC）的方法。还公开了基于KOC1和KIF11或NMU和GHSR1b或NTSR1之间的相互作用鉴定用于治疗和预防NSCLC的化合物的方法。

23. 发明申请

US20090208514A1 METHOD OF DIAGNOSING ESOPHAGEAL CANCER 失效
标题翻译：诊断食管癌的方法
公开(公告)号：US20090208514A1
公开(公告)日：2009-08-20
申请号：US11913170
申请日：2006-07-26
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： A61K39/395 , C12Q1/68 , G01N33/53 , C40B40/06 , A61K31/7052 , A61K39/00 , C12N5/00 , A61K35/12 , A61P35/00 , C07H21/02 , C07K16/00
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , Y10T436/25
摘要： In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, a Homo sapiens epithelial cell transforming sequence 2 oncogene (ECT2) and a cell division cycle 45, S. cerevisiae, homolog-like (CDC45L) are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells. Thus, the data herein provide valuable information for identifying diagnostic systems and therapeutic target molecules for esophageal cancer. Furthermore, the present inventors have identified DKK1 as a potential biomarker for diagnosis of cancer such as lung and esophageal cancers as well as prediction of the poor prognosis of the patients with these diseases. DKK1 was specifically over-expressed in most lung and esophageal cancer tissues the present inventors examined, and was elevated in the sera of a large proportion of patients with these tumors. DKK1, combined with other tumor markers, could significantly improve the sensitivity of cancer diagnosis. Moreover, this molecule is also a likely candidate for development of therapeutic approaches such as antibody therapy.
摘要翻译：为了鉴定涉及食管癌发生的分子以及可用于诊断标志物以及新药和免疫治疗靶标的分子，构建了代表32,256个基因的cDNA微阵列，分析19例食管鳞状细胞癌（ESCCS）的表达谱）通过激光捕获显微切割纯化。本文公开了在食管癌中显着上调或下调的基因组的详细全基因组数据库。这些基因可用于治疗药物或免疫治疗以及肿瘤标志物的开发。此外，本文公开了与淋巴结转移和手术后复发相关的基因。在候选分子靶基因中，进一步表征了人类上皮细胞转化序列2致癌基因（ECT2）和细胞分裂周期45，酿酒酵母，同系物样（CDC45L）。用ECT2或CDC45L的小干扰RNA（siRNA）处理ESCC细胞抑制癌细胞的生长。因此，本文的数据提供了用于鉴定诊断系统和用于食管癌的治疗靶分子的有价值的信息。此外，本发明人鉴定了DKK1作为肺癌，食管癌等癌症诊断用潜在生物标志物，并预测了这些疾病患者的预后差。本发明人检查的大多数肺癌和食管癌组织中DKK1被特异性过度表达，并且在大量患有这些肿瘤的患者的血清中升高。 DKK1与其他肿瘤标志物结合可显着提高癌症诊断的敏感性。此外，该分子也是开发抗体治疗等治疗方法的可能候选者。

24. 发明申请

US20120021946A1 METHOD OF DIAGNOSING ESOPHAGEAL CANCER 有权
标题翻译：诊断食管癌的方法
公开(公告)号：US20120021946A1
公开(公告)日：2012-01-26
申请号：US13246639
申请日：2011-09-27
申请人： Yusuke NAKAMURA , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke NAKAMURA , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： C40B30/04 , G01N33/566
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , Y10T436/25
摘要： In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, ECT2, CDC45L and DKK1 are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells. Thus, the data herein provide valuable information for identifying diagnostic systems and therapeutic target molecules for esophageal cancer.
摘要翻译：为了鉴定涉及食管癌发生的分子以及可用于诊断标志物以及新药和免疫治疗靶标的分子，构建了代表32,256个基因的cDNA微阵列，分析19例食管鳞状细胞癌（ESCCS）的表达谱）通过激光捕获显微切割纯化。本文公开了在食管癌中显着上调或下调的基因组的详细全基因组数据库。这些基因可用于治疗药物或免疫治疗以及肿瘤标志物的开发。此外，本文公开了与淋巴结转移和手术后复发相关的基因。在候选分子靶基因中，进一步表征ECT2，CDC45L和DKK1。用ECT2或CDC45L的小干扰RNA（siRNA）处理ESCC细胞抑制癌细胞的生长。因此，本文的数据提供了用于鉴定诊断系统和用于食管癌的治疗靶分子的有价值的信息。

25. 发明授权

US07972772B2 KIF11 and method for diagnosing non-small cell lung cancer 失效
标题翻译： KIF11及诊断非小细胞肺癌的方法
公开(公告)号：US07972772B2
公开(公告)日：2011-07-05
申请号：US12700669
申请日：2010-02-04
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： C12Q1/00 , C12Q1/68 , A61K48/00 , G01N33/53
CPC分类号： A61K31/731 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： Disclosed are methods for detecting non-small cell lung cancer (NSCLC) using differentially expressed genes KIF11, GHSR1b, NTSR1, and FOXM1. Also disclosed are methods of identifying compounds for treating and preventing NSCLC, based on the interaction between KOC1 and KIF11, or NMU and GHSR1b or NTSR1.
摘要翻译：公开了使用差异表达基因KIF11，GHSR1b，NTSR1和FOXM1检测非小细胞肺癌（NSCLC）的方法。还公开了基于KOC1和KIF11或NMU和GHSR1b或NTSR1之间的相互作用鉴定用于治疗和预防NSCLC的化合物的方法。

26. 发明申请

US20110070245A1 IMP-1 ONCOGENE AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG CANCER 审中-公开
标题翻译： IMP-1 ONCOGENE作为肺癌的治疗目标和预防指标
公开(公告)号：US20110070245A1
公开(公告)日：2011-03-24
申请号：US12377752
申请日：2007-08-16
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： A61K39/395 , C12Q1/68 , C12Q1/02 , G01N33/68 , A61K31/713 , A61K31/7088 , C07H21/02 , C07K16/18 , C40B30/04 , C12N15/63 , A61P35/00
CPC分类号： C12Q1/6886 , C12N15/1135 , C12N2310/14 , C12Q2600/118 , C12Q2600/136
摘要： IMP-1 was abundantly expressed in the majority of lung-cancers examined. Positive immunostaining of IMP-1 was correlated with tumor size (pT-classification; P=0.0003), non-adenocarcinoma histology (P
摘要翻译：在大多数检查的肺癌中IMP-1被大量表达。 IMP-1的阳性免疫染色与肿瘤大小（pT分类; P = 0.0003），非腺癌组织学（P <0.0001），低组织学分级（P = 0.0001）和预后差（P = 0.0053）相关。用siRNA抑制IMP-1表达有效抑制NSCLC细胞的生长。 IMP-1能够结合编码参与信号转导，细胞周期进程，细胞粘附和细胞骨架的各种蛋白质的mRNA，以及各种类型的酶活性。这些结果表明，IMP-1表达可能在肺癌发展和进展中起重要作用，IMP-1是治疗肺癌的预后标志物和有希望的治疗靶点。

27. 发明授权

US07897329B2 Method for diagnosing non-small cell lung cancers by tRNA-dihydrouridine synthase activity of URLC8 失效
标题翻译：通过URLC8的tRNA-二氢尿苷合成酶活性诊断非小细胞肺癌的方法
公开(公告)号：US07897329B2
公开(公告)日：2011-03-01
申请号：US11575812
申请日：2005-09-21
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： C12Q1/00 , G01N33/574
CPC分类号： C12Q1/533 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , G01N33/57423 , G01N2333/99 , G01N2500/02
摘要： The present invention features a method for determining t-RNA dihydrouridine-synthase activity of a polypeptide and screening for modulators of t-RNA dihydrouridine-synthase activity. The present invention further provides methods or pharmaceutical compositions for preventing and/or treating non-small cell lung cancer (NSCLC) using such modulators. Furthermore, the present invention provides methods for diagnosing non-small cell lung cancer (NSCLC) using the t-RNA dihydrouridine-synthase activity of IMS-E21 (URLC8) protein as an index. The present invention further provides methods for predicting and prognosing lung squamous-cell carcinoma (SCC).
摘要翻译：本发明的特征在于测定多肽的t-RNA二氢尿苷合酶活性并筛选t-RNA二氢尿苷合成酶活性的调节剂的方法。本发明还提供了使用这种调节剂预防和/或治疗非小细胞肺癌（NSCLC）的方法或药物组合物。此外，本发明提供使用IMS-E21（URLC8）蛋白的t-RNA二氢尿苷合成酶活性作为指标诊断非小细胞肺癌（NSCLC）的方法。本发明还提供了预测和预测肺鳞状细胞癌（SCC）的方法。

28. 发明申请

US20110014615A1 METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCERS BY tRNA-DIHYDROURIDINE SYNTHASE ACTIVITY OF URLC8 审中-公开
标题翻译： URLC8的tRNA-二氢卟吩合成酶活性诊断非小细胞肺癌的方法
公开(公告)号：US20110014615A1
公开(公告)日：2011-01-20
申请号：US12782641
申请日：2010-05-18
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： C12Q1/68
CPC分类号： C12Q1/533 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , G01N33/57423 , G01N2333/99 , G01N2500/02
摘要： The present invention features a method for determining t-RNA dihydrouridine-synthase activity of a polypeptide and screening for modulators of t-RNA dihydrouridine-synthase activity. The present invention further provides methods or pharmaceutical compositions for preventing and/or treating non-small cell lung cancer (NSCLC) using such modulators. Furthermore, the present invention provides methods for diagnosing non-small cell lung cancer (NSCLC) using the t-RNA dihydrouridine-synthase activity of IMS-E21 (URLC8) protein as an index. The present invention further provides methods for predicting and prognosing lung squamous-cell carcinoma (SCC).
摘要翻译：本发明的特征在于测定多肽的t-RNA二氢尿苷合酶活性并筛选t-RNA二氢尿苷合成酶活性的调节剂的方法。本发明还提供了使用这种调节剂预防和/或治疗非小细胞肺癌（NSCLC）的方法或药物组合物。此外，本发明提供使用IMS-E21（URLC8）蛋白的t-RNA二氢尿苷合成酶活性作为指标诊断非小细胞肺癌（NSCLC）的方法。本发明还提供了预测和预测肺鳞状细胞癌（SCC）的方法。

29. 发明申请

US20100291091A1 CANCER ASSOCIATED GENE LY6K 审中-公开
标题翻译：癌症相关基因LY6K
公开(公告)号：US20100291091A1
公开(公告)日：2010-11-18
申请号：US12671447
申请日：2007-11-21
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： A61K39/395 , C12Q1/68 , G01N33/566 , G01N33/68 , A61K31/7084 , C07H21/00 , C07K16/28 , G01N33/574 , C40B30/00 , A61P35/00
CPC分类号： G01N33/57488 , C07K16/30 , C07K16/3023 , C12N15/113 , C12N15/1135 , C12N2310/14 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , G01N33/5011 , G01N33/57407 , G01N33/57423 , G01N2800/56
摘要： LY6K is identified herein as a potential biomarker useful for the diagnosis of cancer, such as lung and esophageal cancers, as well as for the prognosis of patients with these diseases. As discussed in detail herein, LY6K is specifically over-expressed in most lung and esophageal cancer tissues examined, and is elevated in the sera of a large proportion of patients with these tumors. Accordingly, LY6K may be used in combination with other tumor markers to significantly improve the sensitivity of cancer diagnosis. LY6K may be used in the treatment of ESCC cells, as demonstrated by the fact that small interfering RNAs (siRNAs) of LY6K suppressed growth of the cancer cells. Moreover, the LY6K molecule is also a likely candidate for development of novel therapeutic approaches, such as antibody therapy.
摘要翻译： LY6K在本文中被鉴定为可用于诊断癌症的潜在生物标志物，例如肺和食管癌，以及对这些疾病患者的预后。如本文详细讨论的，LY6K在大多数检查的肺癌和食管癌组织中被特异性过度表达，并且在大部分患有这些肿瘤的患者的血清中升高。因此，LY6K可以与其他肿瘤标记物组合使用，以显着提高癌症诊断的敏感性。 LY6K可用于治疗ESCC细胞，如LY6K的小干扰RNA（siRNA）抑制癌细胞生长的事实所证明的。此外，LY6K分子也是开发新型治疗方法（例如抗体治疗）的可能候选者。

30. 发明申请

US20100184047A1 SCREENING AND THERAPEUTIC METHOD FOR NSCLC TARGETING THE CDCA8-AURKB COMPLEX 审中-公开
标题翻译：用于NSCLC靶向CDCA8-AURKB复合物的筛选和治疗方法
公开(公告)号：US20100184047A1
公开(公告)日：2010-07-22
申请号：US12593265
申请日：2008-03-27
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： C12Q1/68 , G01N33/53
CPC分类号： G01N33/57423 , C12N15/113 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12Y207/01037 , G01N33/5044 , G01N2500/02 , G01N2500/10
摘要： The present invention is based on the observation that the co-activation of CDCA8 and AURKB, and their cognate interactions, play a significant role in lung-cancer progression. Accordingly, inhibiting the formation of the CDCA8-AURKB complex finds utility in the treatment of non-small-cell lung cancer. The present invention also provides methods for identifying for compounds suitable for the treatment and/or prevention non-small-cell lung cancer, using, for example, the transcriptional regulatory region of the CDCA8 or AURKB gene, as well as diagnostic and prognostic methods that utilize the expression levels of CDCA8 and/or AURKB as a determining index.
摘要翻译：本发明基于CDCA8和AURKB的共激活及其同源相互作用在肺癌进展中起重要作用的观察。因此，抑制CDCA8-AURKB复合物的形成可用于治疗非小细胞肺癌。本发明还提供了使用例如CDCA8或AURKB基因的转录调节区鉴定适用于治疗和/或预防非小细胞肺癌的化合物的方法，以及诊断和预后方法，利用CDCA8和/或AURKB的表达水平作为确定指标。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式